Lumbosacral spine and marrow cavity modeling of acute hematologic toxicity in patients treated with intensity modulated radiation therapy for squamous cell carcinoma of the anal canal
Journal
Practical Radiation Oncology
Journal Volume
4
Journal Issue
3
Pages
198-206
Date Issued
2014
Author(s)
Abstract
Purpose: To identify various dosimetric parameters of bone marrow cavity that correlate with acute hematologic toxicity (HT) in patients with anal squamous cell carcinoma treated with definitive chemoradiation therapy (CRT). Methods and materials: We analyzed 32 patients receiving CRT. The whole pelvic bone marrow (PBM) and the lumbosacral spine (LSS) subregion were contoured for each patient. Marrow cavities were contoured using the Hounsfield units (HUs) of 100, 150, 200, and 250 as maximum density threshold levels. The volume of each region receiving at least 5, 10, 15, 20, 30, and 40 Gy was calculated. The endpoint was grade ?. 3 HT (HT3. +). Normal-tissue complication probability (NTCP) was evaluated with the Lyman-Kutcher-Burman (LKB) model. Maximal likelihood estimate was used to compare the parameter set. Logistic regression was used to test associations between HT and both dosimetric and clinical parameters. Results: Ten patients (31%) experienced HT3+. While dose to both LSS and PBM significantly predicted for HT3+, LSS was superior to PBM by logistic regression and LKB modeling. Constrained optimization of the LKB model for HT3+ yielded the parameters m = 0.21, n = 1, and TD50 = 32 Gy for LSS. The NTCP fits were better with the whole bone than with marrow cavity using any HU threshold. Mean LSS doses of 21 Gy and 23.5 Gy result in a 5% and 10% risk of HT3+, respectively. Mean dose and low-dose radiation parameters (V5, V10, V15, V20) of whole bone or bone cavities of LSS were correlated most significantly with HT3+. Conclusions: For predicting the risk of HT3. +, whole-bone contours were superior to marrow cavity and LSS was superior to PBM by LKB modeling. The results confirm PBM and LSS as parallel organs when predicting hematologic toxicity. Recommended dose constraints to the LSS are V10 ?80%. An LSS mean dose of 23.5 Gy is associated with a 10% risk of HT. ? 2014 American Society for Radiation Oncology.
SDGs
Other Subjects
capecitabine; carboplatin; cisplatin; erythropoietin; fluorouracil; hemoglobin; mitomycin; recombinant granulocyte colony stimulating factor; adult; aged; anus carcinoma; article; blood toxicity; blood transfusion; bone marrow; clinical article; disease association; dosimetry; female; hemoglobin blood level; human; intensity modulated radiation therapy; leukocyte count; lumbosacral spine; Lyman Kutcher Burman normal tissue complication probability; male; mathematical analysis; neutrophil count; priority journal; radiation dose; risk reduction; squamous cell carcinoma; thrombocyte count; acute disease; Anus Neoplasms; blood; Bone Marrow Diseases; Carcinoma, Squamous Cell; chemoradiotherapy; computer assisted radiotherapy; Hematologic Diseases; middle aged; Radiation Injuries; very elderly; Acute Disease; Aged; Aged, 80 and over; Anus Neoplasms; Bone Marrow Diseases; Carcinoma, Squamous Cell; Chemoradiotherapy; Female; Hematologic Diseases; Humans; Male; Middle Aged; Radiation Injuries; Radiotherapy Planning, Computer-Assisted
Publisher
Elsevier Inc.
Type
journal article